1. Evolving Treatment Landscape for PsA

3. Multiple Domains of PsA: A Challenge in Diagnosis

4. Treat-to-Target Recommendations

5. MDA Criteria

6. GRAPPA Treatment Schema for Active PsA

7. IL-17: Critical Role in the Pathogenesis of PsA and Psoriasis

8. Agents for the Treatment of PsA

9. Safety and Efficacy of IV Golimumab in Patients With Active PsA: GO-VIBRANT

10. Safety and Efficacy of Ustekinumab, an Anti-IL-12/23 p40 Monoclonal Antibody

11. IL-17 Isoforms, Their Receptors, and Key Molecules Involved in Signal Transduction

12. Bimekizumab: Dual IL-17A and IL-17F Inhibitor

13. IL-17 Inhibitors in PsA: ACR20 Response

14. Efficacy and Safety of IL-17 Inhibitors in Patients With Psoriasis

15. Concomitant Use of MTX With Biologic Therapy

16. IL-17A Inhibitors Prevent Radiographic Progression

17. Efficacy of Secukinumab in Patients With PsA: Results From FUTURE 5

18. Efficacy of Ixekizumab in Patients With PsA: Results From SPIRIT-P1

19. Safety Profile of IL-17 Inhibitors in PsA

20. Efficacy and Safety of Apremilast in Patients With PsA: Results From PALACE 1

21. Efficacy and Safety of Tofacitinib in Patients With PsA

22. Other Non-TNF Biologics in PsA: ACR20 Response

23. CVD in Patients With PsA

24. PsA Treatments and Their Effects on CV Outcomes

25. Weight Gain With Anti-TNF Agents

26. Depression in Patients With PsA

27. PsA: Choice of Therapy

28. Importance of Individualized Therapy for Patients With PsA

29. Holistic Approach to the Management of Patients With Psoriatic Disease

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)